Deutsche Bank maintained a Hold rating on Eli Lilly (NYSE: LLY) with a price target of $85. Shares declined following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib October 13, 2015 8:38 AM Amgen (AMGN), UCB Offer Additional Data from Romosozumab Phase 2October 12, 2015 4:02 PM Eli Lilly (LLY) Eva Failure Increases Dependence on Sola, BMO Capital NotesOctober 12, 2015 11:12 AM Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)October 12, 2015 9:13 AM UPDATE: Esperion (ESPR), Others Gains After Lilly Halts Development of Evacetrapib; Merch (MRK) FallsOctober 12, 2015 8:15 AM Eli Lilly & Co. (LLY) to Discontinue Development of EvacetrapibOctober 12, 2015 8:01 AM Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular DiseaseOctober 12, 2015 8:01 AM